Sagimet Secures $107.5M in Underwritten Offering to Advance Phase 3 Acne Trial
SGMT has more than doubled off its 52-week low of $4.5 on elevated volume (4.5× avg).
Summary
Sagimet priced an underwritten offering of 8.75M shares at $10.00 plus 2.75M pre-funded warrants, expecting $107.5M in net proceeds to fund its Phase 3 acne trial and pipeline advancement. The offering closed with gross proceeds of approximately $115.0M before commissions, discounts, and expenses.
Updated with a Seeking Alpha report · What changed
Updates
· Seeking Alpha — Sagimet closed the offering with gross proceeds of ~$115.0M before commissions, discounts, and expenses.
Key Events · Financing and Capital Events · SGMT
-
Updated · · Seeking Alpha
Offering Closed with Gross Proceeds of ~$115.0M
After underwriting discounts and commissions, net proceeds are expected to be $107.5 million. The offering closed with gross proceeds of approximately $115.0 million before commissions, discounts, and expenses.
-
Underwritten Offering Priced
The offering comprises 8,750,010 shares at $10.00 per share and 2,750,010 pre-funded warrants at $9.9999 per warrant, with an exercise price of $0.0001 per warrant share.
-
Use of Proceeds
Proceeds will fund the Phase 3 AURORA acne trial for denifanstat, pre-launch activities, TVB-3567 through Phase 2 topline results, and the topical FASN inhibitor program to IND submission.
-
Underwriter Syndicate
Leerink Partners, TD Securities, Guggenheim Securities, and Oppenheimer & Co. are joint book-running managers; Canaccord Genuity, H.C. Wainwright, JonesTrading, and Clear Street are co-lead managers.
Analysis · SGMT · Life Sciences
The underwritten offering formalized by Sagimet includes 8.75M shares at $10.00 and 2.75M pre-funded warrants at $9.9999, with net proceeds expected to reach $107.5M. The offering closed with gross proceeds of approximately $115.0M before commissions, discounts, and expenses. These funds are earmarked for the Phase 3 AURORA acne trial, pre-launch activities for denifanstat, and advancing TVB-3567 through Phase 2 topline results. Priced essentially at the current market price of $10.03, the offering signals institutional demand without a deep discount. Existing shareholders face dilution of roughly 11.5M shares, but the raise extends the company's cash runway well beyond its existing $257.6M balance, removing near-term financing risk for the pivotal acne program.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMT was trading at $10.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $608.5M. The 52-week trading range was $4.50 to $11.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.